Cannabinoid Encyclopedia

Focused research review

Cannabinoids and psychiatric risk: what the research says

Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?

Updated July 2026 5 research sources Human research included

The short answer

What is the bottom line?

Research has examined Cannabinoids and psychiatric risk. This page brings together 1 human-study source and 3 research reviews. Human research is included, although its design and scope vary. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Cannabinoids and psychiatric risk.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Cannabinoids and psychiatric risk covers Safety, risk, adverse-event, or formulation-specific concerns; those areas should not be combined into one claim. 1

  2. 2

    Human research is included, although its design and scope vary. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Cannabinoids and psychiatric risk

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, risk, adverse-event, or formulation-specific concerns

This part of the literature focuses on Safety, risk, adverse-event, or formulation-specific concerns. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

1 source

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

3 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

Not prominent

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 5 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on Cannabinoids and psychiatric risk is not one kind of study. This source set includes 2 narrative or expert reviews and 1 systematic review or meta-analysis. 3

The recorded populations or models include people or patients (1 source) and pregnancy, lactation, or reproductive context (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, risk, adverse-event, or formulation-specific concerns (5 sources). Closely related outcome names can still describe different measurements. 5

The Cannabinoids and psychiatric risk source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 1

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.

On this page, this source examines CBD and safety, risk, adverse-event, or formulation-specific concerns. 1

Study type
systematic review or meta-analysis
Population or model
pregnancy, lactation, or reproductive context
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

human research

The contribution of addictovigilance data to the French medical cannabis experimentation.

On this page, this source examines THC and safety, risk, adverse-event, or formulation-specific concerns. 2

Population or model
people or patients
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
human research

narrative or expert review

Cannabis Use and the Risk for Psychosis and Affective Disorders.

On this page, this source examines THC and safety, risk, adverse-event, or formulation-specific concerns. 3

Study type
narrative or expert review
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies.

On this page, this source examines Cannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 4

Study type
narrative or expert review
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

evidence still limited

Cannabis and psychiatric disorders.

On this page, this source examines Cannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 5

Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on Cannabinoids and psychiatric risk should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 1

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?

Relevant research is collected here. Human research is included, although its design and scope vary. 2

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 3

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 4

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. systematic review or meta-analysis; evidence still limited PubMed 37648266 DOI 10.1136/bmj-2022-072348
  2. 2
    The contribution of addictovigilance data to the French medical cannabis experimentation. human research PubMed 39547825 DOI 10.1016/j.therap.2024.10.060
  3. 3
    Cannabis Use and the Risk for Psychosis and Affective Disorders. narrative or expert review; evidence still limited PubMed 31647377 DOI 10.1080/15504263.2019.1674991
  4. 4
    Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. narrative or expert review; evidence still limited PubMed 42309106 DOI 10.1016/s2215-0366(26
  5. 5
    Cannabis and psychiatric disorders. evidence still limited PubMed 20562767
See all 5 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 37648266
  2. Cannabis Use and the Risk for Psychosis and Affective Disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 31647377
  3. Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. narrative or expert review; evidence still limited / 1 linked research note PubMed 42309106
  4. Cannabis and psychiatric disorders. evidence still limited / 1 linked research note PubMed 20562767
  5. The contribution of addictovigilance data to the French medical cannabis experimentation. human research / 1 linked research note PubMed 39547825